» Articles » PMID: 29546072

Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts

Abstract

This policy research aims to map patient access barriers to biologic treatments, to explore how increased uptake of biosimilars may lower these hurdles and to identify factors limiting the increased utilisation of biosimilars. A policy survey was developed to review these questions in 10 Central and Eastern European (CEE) and Commonwealth of Independent States (CIS) countries. Two experts (one public and one private sector representative) from each country completed the survey. Questions were related to patient access, purchasing, clinical practice, and real-world data collection on both original biologics and biosimilars. Restrictions on the number of patients that can be treated and related waiting lists were reported as key patient access barriers. According to respondents, for both clinicians and payers the primary benefit of switching patients to biosimilars would be to treat more patients. However, concerns with therapeutic equivalence and fear of immunogenicity may reduce utilisation of biosimilars. Similar limitations in patient access to both original biologics and biosimilars raise concerns about the appropriateness and success of current biosimilar policies in CEE and CIS countries. The conceptual framework for additional real-world data collection exists in all countries which may provide a basis for future risk-management activities including vigorous pharmacovigilance data collection.

Citing Articles

Regulatory Framework for Supporting the Integration and Use of Biosimilars in the Private Healthcare System of the United Arab Emirates (UAE).

Farghaly M, El-Fass K, Amin N, Qaiser S, Attallah M, Farooq Q Cureus. 2024; 16(11):e74581.

PMID: 39734949 PMC: 11673801. DOI: 10.7759/cureus.74581.


Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review.

Rieger C, Dean J, Hall L, Vasquez P, Merlo G BioDrugs. 2024; 38(4):541-555.

PMID: 38879730 PMC: 11247062. DOI: 10.1007/s40259-024-00659-0.


Maximizing the benefits of using biosimilars in Egypt.

Fasseeh A, Elezbawy B, El-Fass K, GamaI M, Seyam A, Hayek N J Pharm Policy Pract. 2023; 16(1):79.

PMID: 37365620 PMC: 10291771. DOI: 10.1186/s40545-023-00581-w.


Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.

Car E, Vulto A, Houdenhoven M, Huys I, Simoens S Front Pharmacol. 2023; 14:1151764.

PMID: 37153785 PMC: 10160635. DOI: 10.3389/fphar.2023.1151764.


Pharmacists' Perspectives of Biosimilars: A Systematic Review.

Mohd Sani N, Aziz Z, Panickar R, Kamarulzaman A BioDrugs. 2022; 36(4):489-508.

PMID: 35776294 DOI: 10.1007/s40259-022-00541-x.


References
1.
Elek P, Takacs E, Meresz G, Kalo Z . Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries. Health Policy Plan. 2016; 32(3):349-358. DOI: 10.1093/heapol/czw133. View

2.
Ebbers H, Muenzberg M, Schellekens H . The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012; 12(11):1473-85. DOI: 10.1517/14712598.2012.711308. View

3.
Hemmington A, Dalbeth N, Jarrett P, Fraser A, Broom R, Browett P . Medical specialists' attitudes to prescribing biosimilars. Pharmacoepidemiol Drug Saf. 2017; 26(5):570-577. DOI: 10.1002/pds.4186. View

4.
Barosi G, Bosi A, Abbracchio M, Danesi R, Genazzani A, Corradini P . Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2011; 96(7):937-42. PMC: 3128210. DOI: 10.3324/haematol.2011.041210. View

5.
Calo-Fernandez B, Martinez-Hurtado J . Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals (Basel). 2013; 5(12):1393-408. PMC: 3816668. DOI: 10.3390/ph5121393. View